Palisade Bio Inc.’s filing revealed that its Chief Financial Officer Finley John David acquired Company’s shares for reported $2799.0 on Sep 01. In the deal valued at $0.14 per share,19,481 shares were bought. As a result of this transaction, Finley John David now holds 148,727 shares worth roughly $ 13385.43.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Then, Finley John David bought 7,350 shares, generating $1,176 in total proceeds. Upon buying the shares at $0.16, the Chief Financial Officer now owns 129,246 shares.
Before that, Hallam Thomas bought 40,000 shares. Palisade Bio Inc. shares valued at $10,000 were divested by the Chief Executive Officer at a price of $0.25 per share. As a result of the transaction, Hallam Thomas now holds 57,592 shares, worth roughly $5183.28.
Price Performance Review of PALI
On Friday, Palisade Bio Inc. [NASDAQ:PALI] saw its stock jump 2.64% to $0.09. On the same session, the stock had its day’s lowest price of $0.0841, but rose to a high of $0.0885. Over the last five days, the stock has lost -9.80%. Palisade Bio Inc. shares have fallen nearly -93.42% since the year began. Nevertheless, the stocks have fallen -97.03% over the past one year. While a 52-week high of $3.00 was reached on 02/02/22, a 52-week low of $0.08 was recorded on 11/03/22. SMA at 50 days reached $0.1191, while 200 days put it at $0.5490. A total of 0.92 million shares were traded, compared to the trading of 2.15 million shares in the previous session.
Levels Of Support And Resistance For PALI Stock
The 24-hour chart illustrates a support level at 0.0836, which if violated will result in even more drops to 0.0817. On the upside, there is a resistance level at 0.0880. A further resistance level may holdings at 0.0905. The Relative Strength Index (RSI) on the 14-day chart is 34.15, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0099, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.49%. Stochastics %K at 7.46% indicates the stock is a buying.
How much short interest is there in Palisade Bio Inc.?
A steep rise in short interest was recorded in Palisade Bio Inc. stocks on Jul 14, 2022, growing by 60760.0 shares to a total of 0.5 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 0.43 million shares. There was a rise of 12.26%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 2.87% of the overall stock float, the days-to-cover ratio (short ratio) rose to 3.08.
Palisade Bio Inc. [PALI] – Who Are The Largest Shareholders?
In filings from Sargent Investment Group LLC, it is revealed that the company now owns 670,000 shares, or roughly 0.94% of the outstanding PALI shares. In other words, the investor’s shares have risen by 430,000 from its previous 13-F filing of 240000.0. At present, Private Advisor Group LLC is holding 33,500 shares valued at $3317.0. Two Sigma Securities LLC owned 30,513 shares of the company at the time of its most recent 13F filing, worth $3021.0.
According to FactSet, Palisade Bio Inc.’s share price will average $1.50 in the next year, based on opinions of analysts polled by the firm. This is up nearly 1775.0 percent from its previous closing price of $0.08. Analysts expect Palisade Bio Inc. stock to reach the higher price of $1.50, while the lowest price estimate is $1.50. However, 2 analysts have rated PALI stock as an Overweight in their predictions for 2022.